Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials

Annals of Oncology

Volumn 8, Issue 2, 1997, Pages 117-136

  Simonetti, R G ^a   Liberati, A ^b   Angiolini, C ^b   Pagliaro, L ^c  

^a VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

hepatocellular carcinoma; meta analysis; randomized controlled trials; treatment

Indexed keywords

ACIVICIN; ALPHA INTERFERON; AMSACRINE; ANTINEOPLASTIC AGENT; BETA INTERFERON; CARBOPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FLUTAMIDE; GAMMA INTERFERON; INTERFERON; IODINATED POPPYSEED OIL; MEDROXYPROGESTERONE; MENOGARIL; METHOTREXATE; RECOMBINANT INTERLEUKIN 2; SEMUSTINE; STREPTOZOCIN; TAMOXIFEN; TENIPOSIDE; TRIPTORELIN; VINCRISTINE; ZINOSTATIN;

ADULT; AGED; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS, PHASE III; EMBOLIZATION, THERAPEUTIC; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; MALE; RANDOMIZED CONTROLLED TRIALS;

EID: 0031048958     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008285123736     Document Type: Review

References (54)

1. Rustgi VK. Epidemiology of hepatocellular carcinoma. Gastroenterol Clin North Am 1987; 16: 545-51.
2. London WT. Primary hepatocellular carcinoma-etiology, pathogenesis and prevention. Hum Pathol 1981; 12: 1085-97.
3. Lai CL, Gregory PB, Wu PC et al. Hepatocellular carcinoma in Chinese males and females, possible cause for the male predominance. Cancer 1987; 60: 1107-10.
4. Muir C, Waterhouse J, Mack T et al. Cancer Incidence in Five Continents. Vol V. Lyon: IARC Sci Publ 1987; 88.
5. Zamann SN, Johnson PJ, Williams R. Silent cirrhosis in patients with hepatocellular carcinoma. Cancer 1990; 65: 1607-10.
6. Simonetti RG, Fiorello F, Politi F et al. Hepatocellular carcinoma a worldwide problem and the major risk factor. Dig Dis Sci 1991; 36: 962-72.
7. Okuda K. Hepatocellular carcinoma: Recent progress. Hepatology 1992; 15: 948-96.
8. Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: Current status and future directions. Cancer Treat Rev 1988; 15: 1-31.
9. Farinati F, De Maria N, Fornasiero A et al. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Dig Dis Sci 1992; 37: 659-62.
10. Lok AS, Lai CL, Wu PC. Interferon therapy of chronic hepatitis B virus infection in Chinese. J Hepatol 1986; 3: S209-S215.
11. Okamura J, Kawai S, Ogawa M et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma: A comparison between L-TAE with farmorubicin and L-TAE with adriamycin (second cooperative study). Cancer Chemother Pharmacol 1992; 31 (Suppl): S20.
12. Kawai, Tani M, Okamura J et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma: A comparison between L-TAE with farmorubicin and L-TAE with adriamycin: Preliminary results (second cooperative study). Cancer Chemother Pharmacol 1994; 33 (Suppl): S97-S102.
13. Suto T, Fukuda S, Moriya N et al. Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma. Cancer Chemother Pharmacol 1994; 33 (Suppl): S145-S148.
14. Melia WM, Johnson PJ, Williams R. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 1987; 71: 1213-6.
15. Collins R, Yusuf S, Peto R. Overview of randomized trials of diuretics in pregnancy. BMJ 1985; 290: 17-23.
16. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med 1987; 107: 224-33.
17. Falkson G, Moertel CG, Lavin P et al. Chemotherapy studies in primary liver cancer. A prospective randomized clinical trial. Cancer 1978; 42: 2149-56.
18. Melia WM, Johnson PJ, Williams R. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Cancer 1983; 51: 206-10.
19. Choi TK, Lee NW, Wong J. Chemotherapy for advanced hepatocellular carcinoma. Adriamycin vs. quadruple chemotherapy. Cancer 1984; 53: 401-5.
20. Falkson G, MacIntyre J, Moertel CG et al. Primary liver cancer. An eastern Cooperative Oncology group trial. Cancer 1984; 54: 970-7.
21. Falkson G, MacIntery J, Shutt AJ et al. Neocarzinostatin versus mAMSA or doxorubicin in hepatocellular carcinoma. J Clin Oncol 1984; 2: 581-4.
22. Bezwoda WR, Weaving A, Kew M, Derman DP. Combination chemotherapy of hepatocellular cancer. Oncology 1987; 44: 207-9.
23. Falkson G, Ryan LM, Lewis AJ et al. A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer 1987; 60: 2141-5.
24. Lai C-L, Wu P-C, Chan GC-B et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988; 62: 479-83.
25. Falkson G, Cnaan A, Simson IW et al. A randomized phase II study of acivicin and 4′deoxydoxorubicin in patients with hepatocellular carcinoma in an Eastern Cooperative Oncology Group Study. Am J Clin Oncol 1990; 13: 510-5.
26. Kajanti M, Pyrnonen S, Mantyla M, Rissanen P. Intrarterial and intravenous use of 4′epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison. Am J Clin Oncol 1992; 15: 37-40.
27. Farinati F, Salvagnini M, De Maria N et al. Unresectable hepatocellular carcinoma: A prospective controlled trial with tamoxifen. J Hepatol 1990; 11: 297-301.
28. Uchino J, Une Y, Sato Y et al. Chemohormonal therapy of unresectable hepatocellular carcinoma. Am J Clin Oncol 1993, 16: 206-9.
29. Elba S, Giannuzzi V, Misciagna G, Manghisi OG. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Ital J Gastroenterol 1994; 26: 66-8.
30. Martinez Cerezo FJ, Tomas A, Donoso L et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994; 20: 702-6.
31. Manesis EK, Giannoulis G, Zoumboulis P et al. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: A randomized, controlled trial. Hepatology 1995; 21: 1535-42.
32. Castells A, Bruix J, Bró C et al. Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995; 109: 917-22.
33. Lin D-Y, Liaw Y-F, Lee T-Y, Lai C-M. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma. A randomized controlled trial. Gastroenterology 1988; 94: 453-6.
34. Pelletier G, Roche A, Olivier I et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181-4.
35. Yoshikawa M, Sisho H, Ebara M et al. A randomized trial of intrahepatic arterial infusion of 4′epidoxorubicin with lipiodol versus 4″epidoxorubicin alone in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 1994; 33 (Suppl): S149-S152.
36. Madden MV, Krige JEJ, Bailey S et al. Randomized trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993; 34: 1598-600.
37. Groupe d'Etude et de Traitment du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256-61.
38. Kawai S, Okamura J, Ogawa M et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma - a comparison of lipiodoltranscatheter arterial embolization with and without adriamycin (first cooperative study). Cancer Chemother Pharmacol 1992; 31 (Suppl 1): S1-S6.
39. Chang J-M, Tzeng WS et al. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. Cancer 1994; 75: 2449-53.
40. Ikeda K, Inoue H, Yano T et al. Comparison of the anticancer effect of ADMOS alone and ADMOS with CDPP in the treatment of hepatocellular carcinoma by intra-arterial injection. Cancer Chemother Pharmacol 1992; 31 (Suppl): S65-S68.
41. Watanabe S, Nishioka M, Ohta N et al. Prospective and randomized controlled study of chemoembolization therapy in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 1994; 33 (Suppl): S93-S96.
42. Ikeda K, Satoh S, Koida I et al. A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol 1995; 18: 204-10.
43. Izumi R, Shimizu K, Iyobe T et al. Postoperative adjuvant arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 1994; 20: 295-301.
44. Wu CC, Ho YZ, Ho WL et al. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: A reappraisal. Br J Surg 1995; 82: 122-6.
45. Lygidakis NJ, Potoulakis J, Konstantinidou AE, Spanos H. Hepatocellular carcinoma: Surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study. Anticancer Res 1995; 15: 543-50.
46. Lai C-L, Wu P-C, Lok AS-F et al. Recombinant a 2 interferon is superior to doxorubin for inoperable hepatocellular carcinoma: A prospective randomised trial. Br J Cancer 1989; 60: 928-33.
47. Lai C-L, Lau J-YN, Wu P-C et al. Recombinant interferon-a in inoperable hepatocellular carcinoma: A randomized controlled trial. Hepatology 1993; 17: 389-94.
48. Falkson G, Lipsitz S, Borden E et al. Hepatocellular carcinoma. An ECOG randomized phase II study of beta-interferon and menagoril. Am J Clin Oncol 1995; 18: 287-92.
49. Kawata A, Une Y, Hosokawa M et al. Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Am J Clin Oncol 1995; 18: 257-62.
50. Lai E-CS, Choi TK, Tong SW et al. Treatment of unresectable hepatocellular carcinoma: Results of a randomized controlled trial. World J Surg 1986; 10: 501-9.
51. Order S, Pajak T, Leibel S et al. A randomized prospective trial comparing full dose chemotherapy to 131 I Antiferritin: An RTOG study, Int J Radiat Oncol Biol Phys 1991; 20: 953-63.
52. Raoul JL, Guyader D, Bretagne JF et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: Intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994; 35: 1782-7.
53. Falkson G, Cnaan A, Schutt AJ et al. Prognostic factors for survival in hepatocellular carcinoma. Cancer Res 1988; 48: 7314-8.
54. Calvet X, Bruix J, Gines P et al. Prognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patients. Hepatology 1990; 12: 753-60.